<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37652822</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>41</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.</ArticleTitle><Pagination><StartPage>6083</StartPage><EndPage>6092</EndPage><MedlinePgn>6083-6092</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2023.08.055</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(23)01009-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">To inform response strategies, we examined type 1 humoral and intestinal immunity induced by 1) one fractional inactivated poliovirus vaccine (fIPV) dose given with monovalent oral poliovirus vaccine (mOPV1), and 2) mOPV1 versus bivalent OPV (bOPV).</AbstractText><AbstractText Label="METHODS">We conducted a randomized, controlled, open-label trial in Dhaka, Bangladesh. Healthy infants aged 5 weeks were block randomized to one of four arms: mOPV1 at age 6-10-14 weeks/fIPV at 6 weeks (A); mOPV1 at 6-10-14 weeks/fIPV at 10 weeks (B); mOPV1 at 6-10-14 weeks (C); and bOPV at 6-10-14 weeks (D). Immune response at 10 weeks and cumulative response at 14 weeks was assessed among the modified intention-to-treat population, defined as seroconversion from seronegative (&lt;1:8 titers) to seropositive (≥1:8) or a four-fold titer rise among seropositive participants sustained to age 18 weeks. We examined virus shedding after two doses of mOPV1 with and without fIPV, and after the first mOPV1 or bOPV dose. The trial is registered at ClinicalTrials.gov (NCT03722004).</AbstractText><AbstractText Label="FINDINGS">During 18 December 2018 - 23 November 2019, 1,192 infants were enrolled (arms A:301; B:295; C:298; D:298). Immune responses at 14 weeks did not differ after two mOPV1 doses alone (94% [95% CI: 91-97%]) versus two mOPV1 doses with fIPV at 6 weeks (96% [93-98%]) or 10 weeks (96% [93-98%]). Participants who received mOPV1 and fIPV at 10 weeks had significantly lower shedding (p &lt; 0·001) one- and two-weeks later compared with mOPV1 alone. Response to one mOPV1 dose was significantly higher than one bOPV dose (79% versus 67%; p &lt; 0·001) and shedding two-weeks later was significantly higher after mOPV1 (76% versus 56%; p &lt; 0·001) indicating improved vaccine replication. Ninety-nine adverse events were reported, 29 serious including two deaths; none were attributed to study vaccines.</AbstractText><AbstractText Label="INTERPRETATION">Given with the second mOPV1 dose, fIPV improved intestinal immunity but not humoral immunity. One mOPV1 dose induced higher humoral and intestinal immunity than bOPV.</AbstractText><AbstractText Label="FUNDING">U.S. Centers for Disease Control and Prevention.</AbstractText><CopyrightInformation>Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snider</LastName><ForeName>Cynthia J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Khalequ</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA. Electronic address: lxq6@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binte Aziz</LastName><ForeName>Asma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunus</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Warda</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Kathryn A V</ForeName><Initials>KAV</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estivariz</LastName><ForeName>Concepcion F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konopka-Anstadt</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Jaymin C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lickness</LastName><ForeName>Jacquelyn S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steven Oberste</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Abhijeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03722004</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 GH002259</GrantID><Acronym>GH</Acronym><Agency>CGH CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="Y">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bangladesh</Keyword><Keyword MajorTopicYN="N">Humoral immunity</Keyword><Keyword MajorTopicYN="N">Intestinal immunity</Keyword><Keyword MajorTopicYN="N">bOPV</Keyword><Keyword MajorTopicYN="N">fIPV</Keyword><Keyword MajorTopicYN="N">mOPV1</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>22</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37652822</ArticleId><ArticleId IdType="mid">NIHMS1929479</ArticleId><ArticleId IdType="pmc">PMC10895964</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.08.055</ArticleId><ArticleId IdType="pii">S0264-410X(23)01009-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations. 2022. https://www.who.int/publications/i/item/who-wer9724-261-276 (accessed 7 Jul 2022).</Citation></Reference><Reference><Citation>Aylward RB, Sutter RW, Policy HDL. OPV cessation-the final step to a “polio-free” world. Science 2005;310(5748):625–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254173</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio Eradication Strategy 2022-2026: Delivering on a Promise. 2021. https://polioeradication.org/gpei-strategy-2022-2026/(accessed 19 Oct 2022).</Citation></Reference><Reference><Citation>Zaman K, Estivariz CF, Morales M, et al. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial. Lancet Infect Dis 2018;18(6):657–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10495755</ArticleId><ArticleId IdType="pubmed">29571817</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Standard Operating Procedures: Responding to a poliovirus event or outbreak
2022. https://polioeradication.org/wp-content/uploads/2022/07/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220807-EN-Final.pdf (accessed 26 Apr 2022).</Citation></Reference><Reference><Citation>Caceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001;33 (4):531–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11462191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir F, Quadri F, Mach O, et al. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial. Lancet Infect Dis 2015;15(8):889–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644524</ArticleId><ArticleId IdType="pubmed">26093979</ArticleId></ArticleIdList></Reference><Reference><Citation>el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008;359(16):1655–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923170</ArticleId></ArticleIdList></Reference><Reference><Citation>Estivariz CF, Anand A, Gary HE Jr, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis 2015;15(8):898–904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10406135</ArticleId><ArticleId IdType="pubmed">26093980</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010;376 (9753):1682–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20980048</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 - conclusions and recommendations, https://www.ncbi.nlm.nih.gov/pubmed/23696983 (accessed 22 Sep 2018).</Citation></Reference><Reference><Citation>Strategic Advisory Group of Experts on Immunization (SAGE). SAGE October 2022 Meeting Highlights: Strategic Advisory Group of Experts on Immunization (SAGE), 2022. https://cdn.who.int/media/docs/default-source/immunization/sage/2022/october/highlights_sage_oct_2022.pdf?sfvrsn=69f947c4_5 (accessed 18 Oct 2022).</Citation></Reference><Reference><Citation>Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014;345(6199):922–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10389671</ArticleId><ArticleId IdType="pubmed">25146288</ArticleId></ArticleIdList></Reference><Reference><Citation>John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014;384(9953): 1505–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25018120</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993;341(8860): 1545–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">8099637</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent du Chatelet I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003;21(15): 1710–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Suleiman AJ, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000;343(ll):767–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8(4):e1002599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Estivariz CF, Kovacs SD, Mach O. Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks. Vaccine 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10389290</ArticleId><ArticleId IdType="pubmed">35365341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl S, Verma H, Bhatnagar P, et al. Fractional-dose inactivated poliovirus vaccine immunization campaign - Telangana State, India, June 2016. MMWR Morb Mortal Wkly Rep 2016;65(33):859–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27559683</ArticleId></ArticleIdList></Reference><Reference><Citation>Estivariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013;3(3): 309–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10395005</ArticleId><ArticleId IdType="pubmed">23759252</ArticleId></ArticleIdList></Reference><Reference><Citation>John TJ, Jain H, Ravishankar K, et al. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials. Vaccine 2011;29(34):5793–801.</Citation><ArticleIdList><ArticleId IdType="pubmed">21641951</ArticleId></ArticleIdList></Reference><Reference><Citation>Waggie Z, Geldenhuys H, Sutter RW, et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis 2012;205 (2):228–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22158680</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. https://www.goodreports.org/reporting-checklists/consort/(accessed 5 April 2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">20410783</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2): 377–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, REDCap Consortium. The REDCap consortium: Building an international community of software partners. J Biomed Inform 2019;95:103208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization, 2006. https://www.who.int/tools/child-growth-standards/who-multicentre-growth-reference-study (accessed 17 Jul 2018).</Citation></Reference><Reference><Citation>WHO. WHO Policy Statement: Multi-dose Vial Policy (MDVP). Handling of multidose vaccine vials after opening. 2014. https://www.who.int/publications/i/item/WHO-IVB-14.07 (accessed 27 July 2022).</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol 2016;1387:145–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerloff N, Mandelbaum M, Pang H, et al. Direct detection of polioviruses using a recombinant poliovirus receptor. PLoS One 2021,16(11):e0259099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8562806</ArticleId><ArticleId IdType="pubmed">34727100</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington C, Sun H, Jeffries-Miles S, et al. Culture-independent detection of poliovirus in stool samples by direct RNA extraction. Microbiol Spectr 2021;9(3): e0066821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579935</ArticleId><ArticleId IdType="pubmed">34756088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine-live. Plotkin’s vaccines: Elsevier 2018::866–917. el6.</Citation></Reference><Reference><Citation>Connor RI, Brickley EB, Wieland-Alter WF, et al. Mucosal immunity to poliovirus. Mucosal Immunol 2022;15(1):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8732262</ArticleId><ArticleId IdType="pubmed">34239028</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>